Abstract
Summary
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections. The changes in the bronchial walls may be due to chronic inflammation secondary to recurrent or chronic infections in the lung, but often the exact cause is not identified.1 Symptoms vary from intermittent episodes of respiratory infections with excessive mucus production to chronic symptoms with persistent daily expectoration of purulent sputum. Non-cystic fibrosis bronchiectasis is associated with comorbidities such as anxiety, depression, fatigue, and has a significant impact on quality of life.
The global market for Non-Cystic Fibrosis Bronchiectasis was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Non-Cystic Fibrosis Bronchiectasis was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Non-Cystic Fibrosis Bronchiectasis was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Non-Cystic Fibrosis Bronchiectasis was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Non-Cystic Fibrosis Bronchiectasis include Aradigm Corporation, Zambon, Novartis Pharmaceuticals and Insmed Incorporated, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Non-Cystic Fibrosis Bronchiectasis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Non-Cystic Fibrosis Bronchiectasis by region & country, by Type, and by Application.
The Non-Cystic Fibrosis Bronchiectasis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Cystic Fibrosis Bronchiectasis.
Market Segmentation
By Company
Aradigm Corporation
Zambon
Novartis Pharmaceuticals
Insmed Incorporated
Segment by Type:
Oral
Intravenous
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Non-Cystic Fibrosis Bronchiectasis manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Non-Cystic Fibrosis Bronchiectasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Non-Cystic Fibrosis Bronchiectasis in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Non-Cystic Fibrosis Bronchiectasis was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Non-Cystic Fibrosis Bronchiectasis was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Non-Cystic Fibrosis Bronchiectasis was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Non-Cystic Fibrosis Bronchiectasis was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Non-Cystic Fibrosis Bronchiectasis include Aradigm Corporation, Zambon, Novartis Pharmaceuticals and Insmed Incorporated, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Non-Cystic Fibrosis Bronchiectasis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Non-Cystic Fibrosis Bronchiectasis by region & country, by Type, and by Application.
The Non-Cystic Fibrosis Bronchiectasis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Cystic Fibrosis Bronchiectasis.
Market Segmentation
By Company
Aradigm Corporation
Zambon
Novartis Pharmaceuticals
Insmed Incorporated
Segment by Type:
Oral
Intravenous
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Non-Cystic Fibrosis Bronchiectasis manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Non-Cystic Fibrosis Bronchiectasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Non-Cystic Fibrosis Bronchiectasis in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Non-Cystic Fibrosis Bronchiectasis Product Introduction
1.2 Global Non-Cystic Fibrosis Bronchiectasis Market Size Forecast
1.3 Non-Cystic Fibrosis Bronchiectasis Market Trends & Drivers
1.3.1 Non-Cystic Fibrosis Bronchiectasis Industry Trends
1.3.2 Non-Cystic Fibrosis Bronchiectasis Market Drivers & Opportunity
1.3.3 Non-Cystic Fibrosis Bronchiectasis Market Challenges
1.3.4 Non-Cystic Fibrosis Bronchiectasis Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Non-Cystic Fibrosis Bronchiectasis Players Revenue Ranking (2023)
2.2 Global Non-Cystic Fibrosis Bronchiectasis Revenue by Company (2019-2024)
2.3 Key Companies Non-Cystic Fibrosis Bronchiectasis Manufacturing Base Distribution and Headquarters
2.4 Key Companies Non-Cystic Fibrosis Bronchiectasis Product Offered
2.5 Key Companies Time to Begin Mass Production of Non-Cystic Fibrosis Bronchiectasis
2.6 Non-Cystic Fibrosis Bronchiectasis Market Competitive Analysis
2.6.1 Non-Cystic Fibrosis Bronchiectasis Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Non-Cystic Fibrosis Bronchiectasis Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Cystic Fibrosis Bronchiectasis as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral
3.1.2 Intravenous
3.2 Global Non-Cystic Fibrosis Bronchiectasis Sales Value by Type
3.2.1 Global Non-Cystic Fibrosis Bronchiectasis Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Non-Cystic Fibrosis Bronchiectasis Sales Value, by Type (2019-2030)
3.2.3 Global Non-Cystic Fibrosis Bronchiectasis Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Non-Cystic Fibrosis Bronchiectasis Sales Value by Application
4.2.1 Global Non-Cystic Fibrosis Bronchiectasis Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Non-Cystic Fibrosis Bronchiectasis Sales Value, by Application (2019-2030)
4.2.3 Global Non-Cystic Fibrosis Bronchiectasis Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Non-Cystic Fibrosis Bronchiectasis Sales Value by Region
5.1.1 Global Non-Cystic Fibrosis Bronchiectasis Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Non-Cystic Fibrosis Bronchiectasis Sales Value by Region (2019-2024)
5.1.3 Global Non-Cystic Fibrosis Bronchiectasis Sales Value by Region (2025-2030)
5.1.4 Global Non-Cystic Fibrosis Bronchiectasis Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
5.2.2 North America Non-Cystic Fibrosis Bronchiectasis Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
5.3.2 Europe Non-Cystic Fibrosis Bronchiectasis Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
5.4.2 Asia Pacific Non-Cystic Fibrosis Bronchiectasis Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
5.5.2 South America Non-Cystic Fibrosis Bronchiectasis Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
5.6.2 Middle East & Africa Non-Cystic Fibrosis Bronchiectasis Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Non-Cystic Fibrosis Bronchiectasis Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Non-Cystic Fibrosis Bronchiectasis Sales Value
6.3 United States
6.3.1 United States Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
6.3.2 United States Non-Cystic Fibrosis Bronchiectasis Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Non-Cystic Fibrosis Bronchiectasis Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
6.4.2 Europe Non-Cystic Fibrosis Bronchiectasis Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Non-Cystic Fibrosis Bronchiectasis Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
6.5.2 China Non-Cystic Fibrosis Bronchiectasis Sales Value by Type (%), 2023 VS 2030
6.5.3 China Non-Cystic Fibrosis Bronchiectasis Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
6.6.2 Japan Non-Cystic Fibrosis Bronchiectasis Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Non-Cystic Fibrosis Bronchiectasis Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
6.7.2 South Korea Non-Cystic Fibrosis Bronchiectasis Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Non-Cystic Fibrosis Bronchiectasis Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
6.8.2 Southeast Asia Non-Cystic Fibrosis Bronchiectasis Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Non-Cystic Fibrosis Bronchiectasis Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Non-Cystic Fibrosis Bronchiectasis Sales Value, 2019-2030
6.9.2 India Non-Cystic Fibrosis Bronchiectasis Sales Value by Type (%), 2023 VS 2030
6.9.3 India Non-Cystic Fibrosis Bronchiectasis Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Aradigm Corporation
7.1.1 Aradigm Corporation Profile
7.1.2 Aradigm Corporation Main Business
7.1.3 Aradigm Corporation Non-Cystic Fibrosis Bronchiectasis Products, Services and Solutions
7.1.4 Aradigm Corporation Non-Cystic Fibrosis Bronchiectasis Revenue (US$ Million) & (2019-2024)
7.1.5 Aradigm Corporation Recent Developments
7.2 Zambon
7.2.1 Zambon Profile
7.2.2 Zambon Main Business
7.2.3 Zambon Non-Cystic Fibrosis Bronchiectasis Products, Services and Solutions
7.2.4 Zambon Non-Cystic Fibrosis Bronchiectasis Revenue (US$ Million) & (2019-2024)
7.2.5 Zambon Recent Developments
7.3 Novartis Pharmaceuticals
7.3.1 Novartis Pharmaceuticals Profile
7.3.2 Novartis Pharmaceuticals Main Business
7.3.3 Novartis Pharmaceuticals Non-Cystic Fibrosis Bronchiectasis Products, Services and Solutions
7.3.4 Novartis Pharmaceuticals Non-Cystic Fibrosis Bronchiectasis Revenue (US$ Million) & (2019-2024)
7.3.5 Insmed Incorporated Recent Developments
7.4 Insmed Incorporated
7.4.1 Insmed Incorporated Profile
7.4.2 Insmed Incorporated Main Business
7.4.3 Insmed Incorporated Non-Cystic Fibrosis Bronchiectasis Products, Services and Solutions
7.4.4 Insmed Incorporated Non-Cystic Fibrosis Bronchiectasis Revenue (US$ Million) & (2019-2024)
7.4.5 Insmed Incorporated Recent Developments
8 Industry Chain Analysis
8.1 Non-Cystic Fibrosis Bronchiectasis Industrial Chain
8.2 Non-Cystic Fibrosis Bronchiectasis Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Non-Cystic Fibrosis Bronchiectasis Sales Model
8.5.2 Sales Channel
8.5.3 Non-Cystic Fibrosis Bronchiectasis Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer